Positron emission tomography (PET) imaging has become an important diagnostic tool. Various pre‐targeting systems have been reported to address limitations associated with traditional immuno‐PET. However, the application of these mono‐receptor based pre‐targeting (MRPT) strategies is limited to non‐internalizable antibodies, and the tumor uptake is usually much lower than that in the corresponding immuno‐PET. To circumvent these limitations, the first dual‐receptor enhanced pre‐targeting (DRPT) system is developed through entrapping the tumor‐receptor‐specific radioligand by the pre‐administered antibody. Besides the similar ligation pathway happens in MRPT, incorporation of a tumor‐receptor‐specific peptide into the radioligand in DRPT enhances both concentration and retention of the radioligand on tumor, promoting its ligation with pre‐administered antibody on cell‐surface and/or internalized into tumor‐cells. In this study, 64Cu‐based DRPT shows superior performance over corresponding MRPT and immuno‐PET using internalizable antibodies. Besides, the compatibility of DRPT with short‐lived and generator‐produced 68Ga is demonstrated, leveraging its advantage in reducing radio‐dose exposure. Furthermore, the feasibility of reducing the amount of the pre‐administered antibody is confirmed, indicating the cost saving potential of DRPT. In summary, synergizing advantages of dual‐receptor targeting and pre‐targeting, it is expect that this DRPT strategy can become a breakthrough technology in the field of antibody‐based molecular imaging.